Comparing DocGo (NASDAQ:DCGO) and iSpecimen (NASDAQ:ISPC)

iSpecimen (NASDAQ:ISPC) and DocGo (NASDAQ:DCGO) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, dividends, institutional ownership, profitability and earnings.

Profitability

This table compares iSpecimen and DocGo’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
iSpecimen	-139.63%	-285.20%	-114.37%
DocGo	-0.12%	2.52%	1.70%

Volatility & Risk

iSpecimen has a beta of 1.69, indicating that its share price is 69% more volatile than the S&P 500. Comparatively, DocGo has a beta of 0.94, indicating that its share price is 6% less volatile than the S&P 500.

Valuation & Earnings

This table compares iSpecimen and DocGo”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iSpecimen	$9.29 million	0.26	-$12.50 million	($12.89)	-0.07
DocGo	$616.55 million	0.28	$19.99 million	($0.02)	-84.50

DocGo has higher revenue and earnings than iSpecimen. DocGo is trading at a lower price-to-earnings ratio than iSpecimen, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current recommendations for iSpecimen and DocGo, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iSpecimen	0	0	0	0	0.00
DocGo	0	3	3	0	2.50

DocGo has a consensus target price of $3.56, suggesting a potential upside of 110.65%. Given DocGo’s stronger consensus rating and higher possible upside, analysts clearly believe DocGo is more favorable than iSpecimen.

Institutional and Insider Ownership

13.6% of iSpecimen shares are owned by institutional investors. Comparatively, 56.4% of DocGo shares are owned by institutional investors. 12.2% of iSpecimen shares are owned by company insiders. Comparatively, 2.7% of DocGo shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

DocGo beats iSpecimen on 11 of the 14 factors compared between the two stocks.

About iSpecimen

iSpecimen Inc. provides technology that connects life science researchers who need human biofluids, tissues, and living cells for their research with biospecimens available in healthcare provider organizations worldwide. Its cloud-based technology enables scientists to search for specimens and patients across a network of hospitals, clinics, private practice groups, laboratories, blood centers, biobanks, clinical research sites, and cadaveric donation centers. The company develops and operates iSpecimen Marketplace, a proprietary online marketplace platform that connects medical researchers who need access to subjects, samples, and data with hospitals, laboratories, and other organizations who have access to them. It serves biopharmaceutical companies, in vitro diagnostic companies, and government/academic institutions. iSpecimen Inc. was incorporated in 2009 and is headquartered in Lexington, Massachusetts.

About DocGo

DocGo Inc. provides mobile health and medical transportation services for various health care providers in the United States and the United Kingdom. The company's transportation services include emergency response services; and non-emergency transport services comprise ambulance and wheelchair transportation services. It also offers mobile health services through its platform that are performed at home, offices, and other locations; event services, which include on-site healthcare support at sporting events and concerts; and total care management solutions comprising healthcare services and ancillary services, such as shelter. DocGo Inc. was founded in 2015 and is headquartered in New York, New York.